ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01880749
Recruitment Status : Active, not recruiting
First Posted : June 19, 2013
Last Update Posted : July 4, 2018
Sponsor:
Information provided by (Responsible Party):
New York University School of Medicine

June 11, 2013
June 19, 2013
July 4, 2018
June 2013
December 2018   (Final data collection date for primary outcome measure)
Proportions of VS and meningiomas after exposure to RAD001 [ Time Frame: 10 days ]
1) To estimate the proportions of VS and meningiomas with complete inhibition of phospho-S6 after10 days of exposure to RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry. This endpoint was chosen based on prior pharmacodynamic data from a published trial, showing complete inhibition of phospho-S6 in solid tumor tissue of patients treated with RAD001 and our own preliminary data confirming baseline phospho-S6 expression in VS and meningiomas.
Same as current
Complete list of historical versions of study NCT01880749 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry. This is a "phase 0" PK (pharmacokinetic) and PD (pharmacodynamic) study of RAD001 in patients with Neurofibromatosis Type 2-related and sporadic VS and meningiomas. Enrolled patients will take RAD001 prior to a scheduled VS or meningioma surgery, and blood and tissue samples will be obtained for further analysis.
Not Provided
Interventional
Early Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
  • Neurofibromatosis Type 2
  • Vestibular Schwannomas
  • Meningiomas
Drug: RAD001
Other Name: Everolimus
Experimental: RAD001
RAD001 taken by mouth 10mg daily for 10 days before surgery
Intervention: Drug: RAD001
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
5
51
December 2019
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must satisfy all of the following eligibility criteria:
  • Karnofsky performance status (KPS) ≥ 60%
  • Absolute neutrophil count ≥ 1,000/mm³ (unsupported)
  • Platelet count ≥ 100,000/mm³ (unsupported)
  • Hemoglobin ≥ 8 g/dl (transfusion support allowed)
  • Creatinine ≤ 1.5 times upper limit of normal (ULN*) OR corrected glomerular filtration rate ≥ 70 ml/min
  • Total bilirubin ≤ 1.5 times ULN*
  • ALT ≤ 2.5 times ULN*
  • Serum albumin ≥ 2 g/dl
  • INR < 1.3 (or < 3 on anticoagulants)
  • Patients taking a cholesterol-lowering agent must be on a single medication and on a stable dose for at least 4 weeks
  • Fasting serum cholesterol ≤ 300 mg/dl OR ≤ 7.75 mmol/l AND fasting triglycerides ≤ 2.5 times ULN*.
  • Fully recovered from acute toxic effects of any prior chemotherapy, biological modifiers or radiotherapy
  • Any neurologic deficits must be stable for ≥ 1 week
  • Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test. The anti-proliferative activity of this experimental drug may be harmful to the developing fetus.
  • Able to provide written informed consent

Exclusion Criteria:

  • Patients with any of the following are ineligible for this research study:
  • Patients with VS or meningiomas deemed very high surgical risk for stroke and/or other complications by the attending surgeon, such as meningiomas with major vascular or dural sinus infiltration.
  • Patients with serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety.
  • Symptomatic congestive heart failure or unstable angina pectoris.
  • Uncontrolled diabetes, as defined by fasting serum glucose >1.5 times ULN*.
  • Current active hepatic or biliary disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis (with exception of patients with Gilbert's syndrome and asymptomatic gallstones).
  • History of hepatitis B or C. Note: A detailed assessment of hepatitis B/C medical history and risk factors must be done at screening for all patients. HBV serology, DNA and/or HCV RNA PCR testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection. If no positive medical history for risk factors, serology is not required.
  • Seropositivity or DNA/RNA positivity for hepatitis B or C, with the exception of patients who have received prior Hepatitis B vaccination and are Anti-HBs positive only.
  • Known HIV seropositivity
  • Neurologic deficits that are rapidly progressing: all neurologic signs and symptoms must have been stable for a week prior to first dose
  • Patients who are pregnant or breast-feeding. The anti-proliferative activity of this experimental drug may be harmful to the developing fetus or nursing infant.
  • Anti-tumor therapy (i.e. chemotherapeutics or investigational agents or immunotherapy) within 4 weeks prior to enrollment
  • Radiation therapy to a study target lesion within 6 months
  • Prior therapy with mTOR inhibitors, including sirolimus, temsirolimus, deforolimus within 6 months prior to enrollment
  • Known hypersensitivity to RAD001 or other rapamycins (sirolimus, temsirolimus, deforolimus)
  • Patients with a concurrent malignancy
  • Patients treatment with systemic steroids or another immunosuppressive agent. Patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary.
  • Patients cannot receive CYP3A4 inhibiting drugs including antibiotics (clarithromycin, erythromycin, troleandomycin), anti-HIV agents (delaviridine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, lopinavir), antifungals (itraconazole, ketoconazole, fluconazole at doses > 200 mg/day, voriconazole), antidepressants (nefazodone, fluovoxamine), calcium channel blockers (verapamil, diltiazem) oramiodarone
  • Patients should avoid CYP3A4 inhibiting foods including grapefruit and Seville orange juice.
  • Patients cannot receive CYP3A4 inducing anticonvulsants including carbamazepine, felbamate, phenobarbital, phenytoin, primidone and oxcarbazepine, or other CYP3A4 inducers such as St. John's Wort
  • Patients who previously received CYP3A4 inducers or inhibitors must have discontinued these medications within at least 1 week prior to study entry and can re-start them 1 week post-operatively (or earlier if determined to be of clinical benefit, as determined by the treating physician).

    • of institutional norms
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01880749
12-02808
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Not Provided
New York University School of Medicine
New York University School of Medicine
Not Provided
Study Chair: Matthias A Karajannis, MD New York University School of Medicine
New York University School of Medicine
July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP